Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $10.00 Consensus Target Price from Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARMGet Free Report) have been given a consensus rating of “Buy” by the five brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Carisma Therapeutics in a research report on Wednesday, November 29th.

Get Our Latest Stock Report on Carisma Therapeutics

Carisma Therapeutics Stock Performance

Shares of NASDAQ:CARM opened at $2.01 on Monday. The company has a market cap of $81.12 million, a P/E ratio of -0.54 and a beta of 0.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.53 and a current ratio of 7.53. Carisma Therapeutics has a one year low of $1.96 and a one year high of $12.90. The business’s 50-day simple moving average is $2.57 and its 200 day simple moving average is $3.78.

Carisma Therapeutics (NASDAQ:CARMGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.07. The business had revenue of $3.83 million for the quarter. On average, sell-side analysts forecast that Carisma Therapeutics will post -2.64 earnings per share for the current fiscal year.

Institutional Trading of Carisma Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $47,000. Citigroup Inc. acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $70,000. California State Teachers Retirement System acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $78,000. Wells Fargo & Company MN raised its position in Carisma Therapeutics by 1,957.9% during the second quarter. Wells Fargo & Company MN now owns 10,598 shares of the company’s stock valued at $93,000 after buying an additional 10,083 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Carisma Therapeutics by 534.8% during the third quarter. Tower Research Capital LLC TRC now owns 10,982 shares of the company’s stock valued at $46,000 after buying an additional 9,252 shares during the period. Institutional investors own 32.22% of the company’s stock.

About Carisma Therapeutics

(Get Free Report

Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.

Read More

Analyst Recommendations for Carisma Therapeutics (NASDAQ:CARM)

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.